Robert Wise, MD
Pulmonary Disease · Baltimore, MDNPI 1003843657
Payments from drug & device makers
Across 249 payments — averaging $3057.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$226K
- Sanofi US Services Inc.$111K
- GSK$110K
- Chiesi USA, Inc.$84K
- AbbVie$63K
- Astrazeneca UK Limited$57K
- plus $109K from 10 others
Across 65 payments — averaging $3739.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$163K
- Boehringer Ingelheim International GmbH$52K
- Galderma Research & Development, LLC$19K
- Galderma Laboratories, L.p.$6K
- Beyond Air, Inc.$2K
- Sanofi US Services Inc.$918
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $226,477 |
| Sanofi US Services Inc. | 4 | $110,905 |
| GSK | 37 | $110,479 |
| Chiesi USA, Inc. | 13 | $84,192 |
| AbbVie | 19 | $63,350 |
| Astrazeneca UK Limited | 14 | $56,931 |
| Boehringer Ingelheim | 22 | $32,417 |
| E.r. Squibb & Sons, L.L.C. | 5 | $21,700 |
| Merck | 26 | $17,406 |
| Pulmonx Corporation | 13 | $12,062 |
| Novartis | 10 | $9,143 |
| Mylan Inc. | 11 | $6,099 |
| Mylan Specialty L.p. | 11 | $5,281 |
| Boehringer Ingelheim International GmbH | 4 | $3,646 |
| Circassia Inc. | 2 | $1,103 |
| Genentech, Inc. | 1 | $50 |
How this compares
$761,240 in reported general payments places this provider in the 95th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Baltimore
- Alan SchwartzBaltimore$1.6M
- Sonye DanoffBaltimore$1.5M
- Michael DrummondBaltimore$1.4M
- Paul HassounBaltimore$1.3M
- Lonny YarmusBaltimore$1.2M
- Jonathan SevranskyBaltimore$971K
- Nancy LinBaltimore$758K
- Hitesh BatraBaltimore$690K
- Mark LiuBaltimore$503K
- Noah LechtzinBaltimore$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.